Why Healthcare Reform Won’t Be Rushed — And It Isn’t Political
Posted: Apr 1st, 2017In: Opinions & FeaturesRepublicans learned that they must tread carefully in their plans to replace the ACA as the consequences of their actions will result in significant disruption across the healthcare industry.
Read More about Why Healthcare Reform Won’t Be Rushed — And It Isn’t PoliticalTrump, Interest Rates, And Biotech Investing In 2017
Posted: Dec 23rd, 2016In: Opinions & FeaturesWe are heading into 2017 with a great deal of uncertainty, but if President-elect Trump governs the nation as he said he would – unconventionally and unpredictably – we may experience a significant uptick in[...]
Read More about Trump, Interest Rates, And Biotech Investing In 2017Siemens And Northwell Announce Alliance, Enter Big Data Arms Race
Posted: Dec 1st, 2016In: Opinions & FeaturesIn an era where a doctor’s office can generate a terabyte of data easily and toasters can speak to refrigerators, we are in an unprecedented age of information and connectivity.
Read More about Siemens And Northwell Announce Alliance, Enter Big Data Arms RaceAfter Lilly Bombs, Could Alzheimer’s Become Healthcare’s Trumpshot?
Posted: Nov 30th, 2016In: Opinions & FeaturesIf the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructing a skyscraper from the top down–possible, yet at best impractical.
Read More about After Lilly Bombs, Could Alzheimer’s Become Healthcare’s Trumpshot?5 Healthcare Questions That Should (But Won’t) Be Asked At The Debate
Posted: Oct 7th, 2016In: Opinions & FeaturesAs the election draws closer, issue polls consistently rank health care affordability at or near the top of American voters’ concerns.
Read More about 5 Healthcare Questions That Should (But Won’t) Be Asked At The DebateBrexit Will Be Bad For Pharma
Posted: Jun 25th, 2016In: Opinions & FeaturesIn medicine they talk about triage in making quick decisions to save lives. Central bankers and politicians across Europe will be performing financial triage this weekend on the UK and EU.
Read More about Brexit Will Be Bad For PharmaSuperbug Hearing: Will Congress Pick Up Ali’s Fight Against Sepsis?
Posted: Jun 14th, 2016In: Opinions & FeaturesDuring his life, Muhammad Ali did many great things for a great many people. But he may still have another contribution to make to the public, or in this case, for the public’s health.
Read More about Superbug Hearing: Will Congress Pick Up Ali’s Fight Against Sepsis?A Simple Solution To Fixing The Prescription Drug Cost Crisis
Posted: Jun 6th, 2016In: Opinions & FeaturesThe U.S. healthcare system isn't sustainable in its current form with increasing prices, and the disparate approaches to care across states, hospitals, doctors, insurance companies, and income.
Read More about A Simple Solution To Fixing The Prescription Drug Cost CrisisAs Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A
Posted: May 2nd, 2016In: Opinions & FeaturesThe last week was a nonstop whirlwind for biotech, so I’ve decided to treat this entry a little differently by commenting on key events and sharing what I’ve been seeing.
Read More about As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&AWhat Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech
Posted: Apr 22nd, 2016In: Opinions & FeaturesThis week Goldman Sachs announced that its profits fell 60% in a single quarter and blamed a volatile market that’s hit it across business lines.
Read More about What Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech